Lamivudine Tablets (Longaiding / Longze Pharma) – 0.3g × 30 Tablets

Lamivudine Tablets (Longaiding / Longze Pharma) – 0.3g × 30 Tablets

$2.00

Lamivudine Tablets (Longaiding) contain 0.3g of the active antiviral ingredient per tablet. Manufactured by Longze Pharmaceutical, these tablets are commonly used in virology research involving HIV and HBV. For experimental use only.?Please consult staff for other specifications and uses?

EMI starting from $0.00/month - View Plans
Compare

Description

Lamivudine is a synthetic nucleoside analogue used extensively in laboratory studies to evaluate antiviral effects on hepatitis B virus (HBV) and human immunodeficiency virus (HIV). It works as a reverse transcriptase inhibitor, terminating viral DNA synthesis.

The Longaiding formulation, manufactured by Shijiazhuang Longze Pharmaceutical Co., Ltd., delivers 300mg of lamivudine per tablet. Each bottle contains 30 tablets, ideal for controlled lab usage.

?? Note: This product is for research purposes only, not intended for therapeutic use in humans or animals.


Product Specifications

ParameterDetails
Product NameLamivudine Tablets (Longaiding / Longze Pharma)
Active IngredientLamivudine
CAS Number134678-17-4
Molecular FormulaC8H11N3O3S
Molecular Weight229.26 g/mol
Strength0.3g (300 mg) per tablet
Packaging30 tablets per bottle
Dosage FormOral tablets
ManufacturerShijiazhuang Longze Pharmaceutical Co., Ltd.
Approval NumberH20193011 (NMPA)
Product Code86979261000046
Barcode6972238480029
Storage ConditionsStore in a cool, dry place. Avoid direct sunlight.
Shelf LifeAs indicated on the packaging
Intended UseResearch / Experimental use only

Mechanism of Action

Lamivudine is phosphorylated intracellularly to its active triphosphate form, which competitively inhibits viral reverse transcriptase, resulting in DNA chain termination. It’s widely studied for its role in HIV and HBV replication inhibition.


Research Applications

  • Antiviral screening assays

  • HBV DNA polymerase inhibition studies

  • Reverse transcriptase binding research

  • Drug resistance modeling

  • Combination therapy research for HIV/HBV


Safety & Handling

  • For laboratory use only

  • Do not ingest or apply to skin

  • Use appropriate personal protective equipment (PPE)

  • Refer to the SDS for full safety data


Core Keywords

  • Lamivudine 0.3g tablets

  • Lamivudine CAS 134678-17-4

  • Longze Pharmaceutical lamivudine

  • Antiviral research chemicals

  • NRTI HIV research

  • HBV antiviral agents

  • Lamivudine lab use only

  • Experimental use lamivudine

  • Research-grade nucleoside analogues

  • Lamivudine bulk supplier


Research Use Disclaimer

This product is supplied strictly for research and development purposes. It is not for human or veterinary consumption, diagnosis, treatment, or therapeutic use. Use only in controlled laboratory settings by qualified personnel.

Additional information

Weight1 kg
Dimensions38 × 32 × 38 cm

Reviews

There are no reviews yet.

Be the first to review “Lamivudine Tablets (Longaiding / Longze Pharma) – 0.3g × 30 Tablets”

Your email address will not be published. Required fields are marked *

Q1: Is this product safe for human use?

A1: No, this product is strictly for research and laboratory use only.

Q2: What is the CAS number of lamivudine?

A2: CAS number is 134678-17-4.

Q3: What packaging is available?

A3: Each unit contains 30 tablets of 0.3g each.

Q4: Do you support bulk orders?

A4: Yes. We support both wholesale and retail with global shipping options.

Q5: Can I get a Certificate of Analysis (COA)?

A5: Absolutely. COA and MSDS documents are available upon request.


EMI Options

Select at least 2 products
to compare